Regulatory
Sage Therapeutics’ Zulresso (brexanolone) Receives FDA’s Approval for Postpartum Depression
Shots: The approval is based on three clinical studies assessing Zulresso (brexanolone) vs PBO in women with moderate to severe PPD + ≤6 mos. postpartum at screening aged 18 to […]readmore